Patent SG-11201900975X-A (SG)
Title: Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
Inventor: FARR STEPHEN J
IPC: A61P25/08
Filed: 2017-08-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 March 2018 (01.03.2018) o I iolo 011111 00111100110111110 011 (10) International Publication Number WO 2018/037306 Al WIPO I PCT (51) International Patent Classification: A61K 45/06 (2006.01) A61K 31/551 (2006.01) A61K 31/05 (2006.01) A61P 3/04 (2006.01) A61K 31/137 (2006.01) A61P 25/08 (2006.01) A61K 31/36 (2006.01) (21) International Application Number: PCT/IB2017/054740 (22) International Filing Date: 02 August 2017 (02.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/379,183 24 August 2016 (24.08.2016) US 62/515,383 05 June 2017 (05.06.2017) US (71) Applicant: ZOGENIX INTERNATIONAL LIMITED [GB/GB]; Siena Court Broadway, Maidenhead, Berkshire SL6 1NJ (GB). (72) Inventors: FARR, Stephen J.; 12 Roberts Road, Orinda, California 94563 (US). BOYD, Brooks; 2313 Valley Street, Berkeley, California 94702 (US). (74) Agent: CLARK, Andrew Peter; J A Kemp, 14 South Square, Gray's Inn, London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: FORMULATION FOR INHIBITING FORMATION OF 5-HT AGONISTS AND METHODS OF USING SAME 2B Impact of STPNPAJCLB on Fen Exposure Impact of Fen on STPNPA/CLB Exposure Norfen_sim Norfen_obs Fen_sim Fen_obs STP_obs VPA_obs CLB_obs 04 06 08 10 1.2 1.4 16 18 2.0 04 06 0.8 10 12 1.4 1.6 18 20 Change Relative to Monotherapy AUC 0 _ 72 (%) Change Relative to STPNPA/CLB AUC 0 _ 72 (%) AUC 0 . 72.0bs for all analytes was calculated using R (Version 3.3.1) O N FIG. 2 O GC (57) : Drug combinations and their use are disclosed. A first drug is administered in combination with a second drug. The first drug such as fenfluramine is characterized by the formation of a metabolite including 5-HT agonists such as norfenfluramine with 2B O known adverse side effects. The second drug is in the form of a CYP inhibitor such as cannabidiol which modulates the formation of C metabolite down thereby making the first drug safer. [Continued on next page] WO 2018/037306 Al MIDEDIMOMMIDIREIHNIMIIMEHINIMERVOIS EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))